Download This PaperSARS-CoV-2, COVID-19, Infection Fatality Rate (IFR) Implied by the Serology, Antibody, Testing in New York City
22 Pages Posted: 11 May 2020 Last revised: 9 Nov 2023
There are 2 versions of this paper
SARS-CoV-2, COVID-19, Infection Fatality Rate (IFR) Implied by the Serology, Antibody, Testing in New York City
Sars-Cov-2, Covid-19, Infection Fatality Rate (Ifr) Implied by the Serology, Antibody, Testing in New York City
Date Written: November 6, 2023
Abstract
This paper estimates SARS-CoV-2, COVID-19, infection fatality rate (IFR) in early 2020 before pharmaceutical interventions were available on a large population in the United States. The better estimates of COVID-19 deaths in New York City and its high COVID-19 infection rate made it ideal to accurately estimate the IFR. We survey serology, antibody, studies of the COVID-19 infection to find official cases are understated by an average of 25-to-1. Further, we analyze the deaths and infections in New York City to estimate an overall IFR for the United States of 0.863 percent.
Note: Funding: We have received no funding to write this study.
Conflict of Interest: We have no conflicts of interest.
Keywords: antibody, CFR, COVID-19, death rates, IFR, New York City, SARS-CoV-2, serology, seroprevalance
JEL Classification: G22, I1, I18, J31, J65, K32
Suggested Citation: Suggested Citation